Skip to main content

Gene Therapy Deal Benchmarks in Women's Health

Median Upfront
$319M
Range: $166M - $471M
Total Deal Value
$1.8B
Range: $1.1B - $2.4B
Royalty Rate
7.8% - 15.7%
Tiered up to 19.7%
Dev Milestones
$315M
Range: $202M - $428M
Model Your Deal

Market Analysis

Gene Therapy therapies in women's health have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in women's health is $319M, with total deal values reaching $1.8B. Development milestones average $315M, while regulatory milestones contribute $329M.

The women's health gene therapy landscape is characterized by moderate competitive intensity with significant historical underinvestment creating unmet need. Novel hormonal approaches, non-hormonal alternatives for menopause, and precision medicine in endometriosis are driving renewed deal-making activity. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for gene therapy women's health deals range from 7.8% to 15.7% at the base tier, with tiered escalation reaching 11.8%-19.7% on blockbuster sales. Commercial milestones averaging $787M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a gene therapy women's health licensing deal?
Based on our analysis, Phase 2 gene therapy licensing deals in women's health average $319M in upfront payments, with a range of $166M to $471M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for gene therapy women's health transactions?
The median total deal value for Phase 2 gene therapy assets in women's health is $1.8B, ranging from $1.1B to $2.4B. This includes development milestones ($315M), regulatory milestones ($329M), and commercial milestones ($787M).
What royalty rates are standard for gene therapy deals in women's health?
Base royalty rates for gene therapy women's health transactions range from 7.8% to 15.7%, with tiered escalations reaching 11.8%-19.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in gene therapy women's health deals?
Gene Therapy women's health deals allocate approximately 82% of total deal value to milestones. Development milestones ($315M) make up the largest share, followed by commercial milestones ($787M) and regulatory milestones ($329M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Women's Health

View

Monoclonal Antibody in Women's Health

View

Gene Therapy in Oncology

View

Gene Therapy in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included